Skip links

Our Product Categories

Med Aditus has identified three classes of drugs for local manufacture in sub-Saharan Africa initially based on unmet need and market potential.

Medicines for Pediatric Populations

In 2020, there were 200 million children aged 0-4 years in Africa and as of 2021, 40% of the population in Africa is aged 15 years and younger. Yet, very few medicines consumed by children in Africa are formulated for children, leading to treatment that is inadequate and potentially harmful. Med Aditus plans to specialize in pediatric medicines.

The population of sub-Saharan Africa is projected to double by 2050 (that constitutes a 99 percent increase). Almost 60 percent of Africa’s population is under the age of 25, making Africa the world’s youngest continent.


Medicines for Neglected Tropical Diseases (NTDs)

The drugs for “neglected tropical diseases,” (NTDs) diseases caused by parasitic and other infections in tropical countries, are developed by nonprofit global health institutions and some pharmaceutical companies. These drugs are manufactured by a few pharmaceutical companies as a humanitarian effort and distributed to countries where the diseases are endemic under a donor program coordinated by World Health Organization. Donation-only programs for treating and preventing these diseases are not sustainable indefinitely. Med Aditus plans to work with the key players in the donor program to develop local manufacturing capacity for NTD drugs in Sub-Saharan Africa and catalyze a transition from a total dependence of the countries on donor programs to self-reliance for treating NTDs in the region.

The neglected tropical diseases (NTDs) are the most common conditions affecting the poorest 500 million people living in sub-Saharan Africa (SSA) and together produce a burden of disease that may be equivalent to up to one-half of SSA’s malaria disease burden and more than double that caused by tuberculosis.


Medicines for Non-Communicable Diseases (NCDs)

NCDs kill 41 million people each year (71 percent of deaths). Seventy-seven percent of these deaths are from low-and-middle-income countries. According to a paper published in The Lancet Global Health, NCDs are set to become the leading cause of death in sub-Saharan Africa by 2030. Cardiovascular diseases and diabetes, in particular, will soon overtake as primary disease burdens. Med Aditus seeks to make a significant impact in the lives of patients in sub-Saharan Africa by producing drugs locally to treat rapidly rising NCDs.

Diabetes is particularly devastating in sub-Saharan Africa from both an economic and a health care standpoint. Diabetes in sub-Saharan Africa is associated with the highest rate of morbidity and mortality in the world, particularly in the population who are able to work.